Ironwood Pharmaceuticals, Inc.

What they do

Ironwood develops and commercializes therapies for gastrointestinal and rare diseases and operates in one reportable segment, human therapeutics. Its commercial product is LINZESS (linaclotide), a GC-C agonist approved in the U.S. for IBS-C, CIC and functional constipation. Linaclotide is commercialized through partnerships with AbbVie in the U.S. and most worldwide markets, Grand Life Sciences in China, and Astellas in Japan. Apraglutide, a long-acting GLP-2 analog acquired with VectivBio in June 2023, is in development for short bowel syndrome with intestinal failure.

Revenue drivers

• U.S. LINZESS collaboration (AbbVie) — Ironwood and AbbVie share equally in U.S. brand collaboration profits; Ironwood recognized $289.3 million of collaborative arrangements revenue tied to U.S. LINZESS in 2025, down $51.1 million from 2024.
• Ex-U.S. linaclotide partnerships — Linaclotide is sold by partners in China, Japan, Mexico, Saudi Arabia, Canada (as CONSTELLA) and certain European countries; in May 2026 AstraZeneca assigned its China collaboration to Grand Life Sciences.
• U.S. LINZESS end-market sales — Reported by partner AbbVie: $282.3 million in Q2 2026, up 14% from $248.0 million in Q2 2025; $555 million year-to-date 2026, representing 44% year-over-year growth.
• Apraglutide — Not yet an approved product and generates no revenue; a confirmatory Phase 3 trial (STARS-2) is required before any NDA submission for SBS-IF.

Recent performance

Q2 2026 total revenue was $113.0 million versus $85.2 million in Q2 2025, with GAAP net income of $51.3 million ($0.31 diluted) versus $23.6 million ($0.14 diluted). U.S. LINZESS net sales were $282.3 million in Q2 2026, up 14% year over year, on 4% capsule demand growth and improved net price; commercial margin was 78% versus 69% a year earlier. Ironwood repaid $200 million of convertible notes with cash on hand during the quarter. For the six months ended June 30, 2026, net income was $92.1 million. Full-year revenue has declined each year from $442.7 million in 2023 to $296.2 million in 2025.

Strategy

Management states three priorities: maximizing LINZESS, advancing apraglutide, and delivering sustained profits and cash flow. In June 2026 the company initiated STARS-2, a 24-week global, randomized, double-blind, placebo-controlled confirmatory Phase 3 trial of apraglutide in SBS-IF, and is recruiting patients. The primary endpoint measures relative change from baseline in actual weekly parenteral support. The company says it remains committed to further debt reduction and strengthening the balance sheet through year end.

Risks

• Single-product concentration — Ironwood states it is highly dependent on the commercial success of U.S. LINZESS for the foreseeable future, and that collaboration revenue is a significant portion of total revenue.
• Apraglutide regulatory delay — A previously completed Phase 3 (STARS) was insufficient for an NDA because delivered exposure and dose were lower than planned, forcing the confirmatory STARS-2 trial now recruiting.
• Negative shareholder equity — At June 30, 2026 total liabilities of $447.0 million exceeded total assets of $285.1 million, producing shareholder equity of negative $161.8 million.
• Pricing and reimbursement pressure — LINZESS results depend on coverage and reimbursement levels set by government authorities and third-party payors, and the 2025 revenue decline was driven partly by net price.

Outlook

Ironwood raised full-year 2026 guidance: U.S. LINZESS net sales of $1.15–$1.20 billion (greater than 30% year-over-year growth), total revenue of $460–$485 million, and adjusted EBITDA greater than $310 million. The guidance assumes mid-single-digit percentage demand growth. Management also points to STARS-2 recruiting and the goal that apraglutide would be the first long-acting GLP-2 analog to market.